The FDA has signed off on Sanofi’s oral drug venglustat to treat patients with type 3 Gaucher disease over a certain weight.
The once-daily pill, to be sold under the brand name Infilbray, is the first medicine approved by the agency that targets the neurological symptoms of the disease, according to the FDA’s announcement of the approval Wednesday evening.